Feature | May 14, 2014

Study Shows Significant Overall Cost Savings Using Quadripolar System

Comparative effectiveness study shows use of quadripolar technology reduces hospital utilization and lowers overall costs

May 14, 2014 — Data presented during Heart Rhythm 2014 found the use of quadripolar leads reduced the number of hospitalizations by 53 percent when compared to the non-quadripolar group. This hospitalization rate reduction translated into a statistically significant 62 percent reduction in overall costs for both healthcare systems and patients.

The “Hospitalization Rates and Associated Cost Analysis of Quadripolar versus Bipolar CRT-D: a comparative analysis of a single-center prospective Italian registry” presentation included data that demonstrated hospitalization rates for the quadripolar group were lower than the non-quadripolar group, and patients with the St. Jude Medical Quartet quadripolar LV (left ventricular) lead had a 98 percent probability of having lower costs than patients with non-quadripolar leads. The study showed that use of the quadripolar LV lead was associated with significantly reduced hospitalizations specific to the two types of hospitalizations studied: heart failure and LV lead surgical revision.

“These data are compelling evidence as they show a significant cost saving for the healthcare system and patients utilizing the St. Jude Medical quadripolar pacing system,” said Giovanni Forleo, M.D., electrophysiologist at the University Hospital of Tor Vergata in Rome. “This study showed a strong cost benefit, further demonstrating why quadripolar technology is becoming the standard-of-care for patients requiring CRT [cardiac resynchronization therapy].”

The prospective, single-center, observational registry was a first-time evaluation of hospitalization rates and cost reduction following CRT with quadripolar versus non-quadripolar LV leads. Over three years, 198 patients implanted with either a St. Jude Medical Quartet quadripolar LV lead or a non-quadripolar LV lead, were enrolled in the study. The goal of the study was to compare the hospitalization rate related to heart failure and LV lead surgical revisions between the Quartet quadripolar lead and a traditional bipolar lead for cardiac resynchronization therapy defibrillators (CRT-Ds).

“This study provides additional evidence that the quadripolar system improves patient outcomes and reduces healthcare costs,” said Mark D. Carlson, M.D., chief medical officer and vice president of global clinical affairs for St. Jude Medical. “This study is another example of St. Jude Medical’s commitment to investing in disruptive technologies that transform the treatment of expensive epidemic diseases.”

For more information: www.sjm.com

Related Content

INRatio, Alere, Abbott, I and R testing, INR testing
Feature | Point of Care Testing| December 07, 2016
December 7, 2016 — Abbott has filed a complaint to terminate its proposed acquisition of Alere based on the substanti
Vascular Solutions, Teleflex
Feature | December 07, 2016
December 7, 2016 — Teleflex Inc. and Vascular Solutions Inc.
TCT 2016, TCT.16, main arena, late breaking trials, transcatheter cardiovascular therapeutics

There were several hot topics that came out of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting Oct. 29 - Nov. 2, which made this month's top 20 list, including several videos. Number 4 on the list of content was the result of the EXCEL Trial key TCT late-breaker, which showed stenting is equal in outcomes to surgery for the first time, when using one of the latest generation drug-eluting stents. 

Feature | December 05, 2016
December 5, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional
Cardioband, valtech, Edwards Lifesciences, transcatheter mitral repair, transcatheter tricuspid valve repair, transcatheter annuloplasty

An illustration of how the transcatheter Cardioband System can used as a non-surgical form on annuloplasty repair. 

News | Heart Valve Technology| December 02, 2016
December 2, 2016 — Edwards Lifesciences Corp.
Boston Scientific, HeartLogic Heart Failure Diagnostic Service, MultiSENSE trial data, AHA Scientific Sessions 2016
News | Heart Failure| November 18, 2016
Boston Scientific recently announced results from the first clinical trial evaluating the performance of the HeartLogic...
atrial fibrillation, warfarin, dementia, Intermountain Medical Center Heart Institute, American Heart Association, AHA Scientific Sessions 2016
News | Atrial Fibrillation| November 15, 2016
Atrial fibrillation patients who use warfarin to lower risk of stroke are at higher risk of developing dementia than...
Medtronic, Claria MRI Quad CRT-D SureScan, FDA approval
Technology | Cardiac Resynchronization Therapy Devices (CRT)| November 15, 2016
Medtronic plc  has received U.S. Food and Drug Administration (FDA) approval for the Claria MRI Quad Cardiac...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Sponsored Content | Videos | Heart Valve Technology| November 14, 2016
William Abraham, M.D., FACC, discusses advances in heart failure device treatment technologies at the Transcatheter C
Siemens, Healthineers, public listing, healthcare business
News | Business| November 11, 2016
Siemens announced it intends to further develop its healthcare business, Siemens Healthineers, and give it even greater...
Overlay Init